Investment analysts at StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the basic materials company’s stock.
Arcadia Biosciences Stock Performance
NASDAQ:RKDA opened at $4.39 on Wednesday. The stock has a 50-day simple moving average of $5.33 and a 200-day simple moving average of $3.99. The stock has a market cap of $5.97 million, a P/E ratio of -1.03 and a beta of 0.88. Arcadia Biosciences has a 1 year low of $1.85 and a 1 year high of $10.31.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Arcadia Biosciences stock. Geode Capital Management LLC acquired a new position in shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned approximately 0.90% of Arcadia Biosciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 17.73% of the company’s stock.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- 5 discounted opportunities for dividend growth investors
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- How to Use Stock Screeners to Find Stocks
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.